ライフサイエンスコーパス: nonocular

1 es were incidence and severity of ocular and nonocular adverse events (AEs).

2 ty statistics, the frequencies of ocular and nonocular adverse events seemed to be slightly higher am

3 No nonocular adverse events were considered related to stud

4 No serious nonocular adverse events were reported.

5 The primary safety measures were ocular and nonocular adverse events.

6 Main nonocular AEs were hypertension and nasopharyngitis (9.0

7 The main nonocular AEs were nasopharyngitis (18.8%) and hypertens

8 Study eye ocular adverse events (AEs) and nonocular AEs were similar between treatment groups.

9 ic metastatic disease, then treatment of the nonocular and ocular metastatic tumors consists of chemo

10 reported, with 93% described as mild, 95% as nonocular, and only 14% deemed possibly caused by the in

11 s with TCF8 mutations should be examined for nonocular anomalies.

12 may be more effective for rheumatologic and nonocular autoimmune disorders than for uveitis.

13 upports current standard of care to pursue a nonocular biopsy of normal-appearing, perilesional skin

14 imaging uncovered previously occult primary nonocular cancers (11/18, 61%), revealed progression of

15 reports, involving some types of autologous, nonocular cell sources, have been linked to severe, blin

16 ial cells, although receptors on a few other nonocular cell types also have been described.

17 Severity of ocular pain correlates with nonocular comorbidities such as use of antidepressant me

18 ntified sociodemographic factors, ocular and nonocular conditions associated with incident BRVO.

19 PET/CT findings were used to direct nonocular, confirmatory biopsy in 67% of cases (12/18).

20 er factor, stimulates growth and motility in nonocular endothelial cells and smooth muscle cells thro

21 bizumab therapy in DME was not influenced by nonocular factors related to systemic management of diab

22 The nonocular features included white forelock in 4 of 7 (57

23 l 9 had abusive head trauma diagnosable with nonocular findings.

24 ients with DME, with low rates of ocular and nonocular harm.

25 ular events (OR, 1.18; 95% CI, 0.81-1.71) or nonocular hemorrhagic events (OR, 1.42; 95% CI, 0.95-2.1

26 ular events (OR, 0.94; 95% CI, 0.59-1.52) or nonocular hemorrhagic events (OR, 2.56; 95% CI, 0.78-8.3

27 Increased risks of VTEs with bevacizumab and nonocular hemorrhagic events in older patients with AMD

28 up analysis showed a significant increase of nonocular hemorrhagic events in patients with AMD in ran

29 ificant increases in major cardiovascular or nonocular hemorrhagic events, but studies and meta-analy

30 ary end points were major cardiovascular and nonocular hemorrhagic events.

31 keratitis (HSK) were compared with sera from nonocular HSV-1-seropositive and HSV-seronegative contro

32 ma suspect, ocular hypertension, or non-POAG/nonocular hypertension.

33 of VCPs), but other ocular test results and nonocular information were infrequently obtained.

34 ve munitions cause high rates of concomitant nonocular injuries such as traumatic brain injury, amput

35 ched more than fivefold over other published nonocular libraries.

36 the retinal vasculature, retina, and several nonocular organs (lungs, liver, and spleen).

37 sttraumatic stress disorder and depression), nonocular pain, and medications (eg, anxiolytics and ana

38 nally, such as psychiatric comorbidities and nonocular pain, were also associated with severe dry eye

39 Pseudomonas aeruginosa was expressed in the nonocular pathogenic host, Pseudomonas putida, to elucid

40 All patients with nonocular phenotypic abnormalities had detectable mutati

41 A) probands, including five with additional, nonocular phenotypic abnormalities.

42 Nonocular risk factors included sleep disturbances (eg,

43 Furthermore, nonocular risk factors that have been associated with dr

44 The incidence of nonocular SAEs was 8.8% in the IAI group and 9.8% in the

45 es of endophthalmitis, and the incidences of nonocular SAEs were low.

46 No new ocular or nonocular safety events were observed.

47 There were no new ocular or nonocular safety events.

48 No new ocular or nonocular safety findings were observed during the study

49 parison of these libraries with 100 reported nonocular SAGE libraries revealed 89 retina-specific or

50 Incidences of nonocular serious AEs generally were well balanced betwe

51 tudy the effects of CsA on angiogenesis in a nonocular site.

52 cle, iris, ciliary body, cornea, and several nonocular sites, such as heart and nasal epithelium.

53 GM1 eliminated NK activity in the eye and at nonocular sites.

54 and biochemically unique when compared with nonocular skeletal muscles.

55 nsistent with resistance trends reported for nonocular staphylococcal isolates.

56 t common ocular complication associated with nonocular surgery, but toxic keratopathy is rare.

57 n association of exfoliation syndrome with a nonocular systemic condition.

58 ure to dexamethasone after iontophoresis; no nonocular systemic corticosteroid-mediated effects were

59 In nonocular systems, activation of opioid receptors has be

60 y alter vascular permeability in a number of nonocular tissues via Src kinase-regulated signaling pat

61 Retinoid levels in nonocular tissues were also analyzed for comparison.

62 vascular hyperpermeability in all ocular and nonocular tissues, prevented the increase in vascular co

63 h myocilin is detected in several ocular and nonocular tissues, the only reported human pathology rel

64 ppress TGF-beta-induced fibrogenesis in many nonocular tissues.

65 levels were higher in mouse eyecups than in nonocular tissues.

66 be less than if transplanted cells are from nonocular tissues.

67 t, and prevention of apoptotic cell death in nonocular tissues.

68 ation and a known vasopermeability factor in nonocular tissues.

69 elationship between ICP and other ocular and nonocular variables was performed by using univariate an